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Abstract
Introduction Rheumatoid arthritis (RA) is a heterogeneous
disease and its underlying molecular mechanisms are still poorly
understood. Because previous microarray studies have only
focused on long-standing (LS) RA compared to osteoarthritis,
we aimed to compare the molecular profiles of early and LS RA
versus control synovia.
Methods Synovial biopsies were obtained by arthroscopy from
15 patients (4 early untreated RA, 4 treated LS RA and 7
controls, who had traumatic or mechanical lesions). Extracted
mRNAs were used for large-scale gene-expression profiling.
The different gene-expression combinations identified by
comparison of profiles of early, LS RA and healthy synovia were
linked to the biological processes involved in each situation.
Results Three combinations of 719, 116 and 52 transcripts
discriminated, respectively, early from LS RA, and early or LS RA
from healthy synovia. We identified several gene clusters and
distinct molecular signatures specifically expressed during early
or LS RA, thereby suggesting the involvement of different
pathophysiological mechanisms during the course of RA.
Conclusions Early and LS RA have distinct molecular
signatures with different biological processes participating at
different times during the course of the disease. These results
suggest that better knowledge of the main biological processes
involved at a given RA stage might help to choose the most
appropriate treatment.
Introduction
Rheumatoid arthritis (RA) is a chronic, autoimmune, and
inflammatory polyarthritis that induces joint damage and disa-
bility. It is a heterogeneous disease with different clinical pres-
entations and courses, ranging from mild to severe.
Histological and molecular variations in synovial tissues were
previously described among RA patients [1,2]. However, the
few microarray studies available were conducted on human
RA synovia from patients with long-standing (LS) disease and/
or treated with disease-modifying antirheumatic drugs
(DMARDs) and/or glucocorticoids [2-4]. Moreover, many
studies used osteoarthritis synovia as the control because of
the difficulties in obtaining healthy synovial samples [5-8]. The
molecular differences observed in those comparisons did not
aRNA: antisense RNA; DMARD: disease-modifying antirheumatic drug; LS: long-standing; MHC: major histocompatibility complex; PANTHER: Pro-
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precisely indicate the pathological processes involved in RA,
especially if we consider that different biological processes
are at work throughout the course of RA. The tight link
between the molecular pattern and the disease stage was pre-
viously described in murine autoimmune arthritis but no data
are available on human RA [9]. Therefore, we applied gene-
expression profiling to synovial biopsies from patients with
early untreated or treated LS RA and control synovia to try to
identify biological processes corresponding to the RA stages.
Materials and methods
Patients
Synovial tissue biopsies were obtained by arthroscopy from
four untreated patients with early RA, four treated patients with
LS RA, and seven patients undergoing knee arthroscopy for
traumatic or mechanical ligament or meniscus lesions. This
protocol (00/149 HP) was approved by our regional ethics
committee (CPP Nord-Ouest 1, formerly CCPPRB Haute-
Normandie, France), and all participants gave their written
informed consent. Clinical and demographic data for these 15
patients are summarized in Table S1 of Additional data file 1.
Three of the four early RA patients had rheumatoid factors
and/or anti-cyclic citrullinated peptide (n = 1) autoantibodies
or structural damage (n = 2) (that is, the main RA characteris-
tics). All early RA patients were untreated (that is, they had not
yet been prescribed DMARDs or glucocorticoids), whereas all
LS RA patients were taking oral methotrexate. All biopsies
were taken from inflamed synovial sites, with at least three
samples being taken and pooled to minimize the heterogeneity
of cellular infiltrates and fibrosis among them.
Sample preparation and cDNA arrays
A standard phenol-chloroform procedure was used to extract
total RNAs from synovial tissue, and quality was controlled on
an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa
Clara, CA, USA). mRNAs were amplified linearly using the
MessageAmp™ aRNA [antisense RNA] Kit (Ambion, now part
of Applied Biosystems, Huntingdon, UK) in accordance with
the instructions of the manufacturer. aRNAs were labeled with
[α-33P]dCTP. The resulting labeled cDNAs were immediately
used for hybridization on an array covering about 10,000 non-
redundant genes, as described and validated previously
[10,11]. Each RNA sample was hybridized three times on sep-
arate arrays.
Image analysis and data mining
The scanned 16-bit image was imported into a Linux worksta-
tion and the spots were automatically identified and analyzed
with XDotsReader software, version 1.8 (COSE, Dugny,
France) [10]. Spots were identified with the 'algorithm 2'
option (that is, spot morphology is the critical parameter), and
every spot within an array was quantitated with the 'weighted
mean intensity' option (that is, the average of the pixel intensi-
ties of the spot is weighted by the distance to the center of this
spot). Because of the background homogeneity in our array, a
global background over the entire image was calculated as the
mean of the local background measured around each spot
('global background' option) and it was automatically sub-
tracted from every spot signal. Next, the mean signal associ-
ated with negative control spots was calculated over the entire
image. For all genes considered, a spot whose signal was
below a given threshold (2 standard deviations above the
mean signal for negative controls) was considered to be non-
significant (P < 0.05). Finally, the mean signal associated with
negative control spots was automatically subtracted from the
signal of every significant spot. To be able to compare images,
the mean of the signals provided by the complete set of spots
per image served as the basis for normalization.
A transcript was considered to be expressed when at least
two hybridizations provided a positive signal. The TIGR Multi-
Experiment Viewer [12] was used for unsupervised hierarchi-
cal clustering by applying the average dot product and
complete linkage options, and the supervised statistical tools
one-class t test with the adjusted Bonferroni correction was
used for identification of discriminant transcripts. Adjusted
Bonferroni P values of less than 0.01 were considered signifi-
cant.
To determine which biological processes were represented by
the differences in gene-expression levels for each comparison
(early versus LS RA; early RA or LS RA versus controls), we
applied gene-ontology analysis using the PANTHER (Protein
ANalysis THrough Evolutionary Relationships) database [13-
15]. Genes with eligible symbols available and being catego-
rized by gene-ontology terms were retained. We used the
PANTHER binomial statistics tool to compare classifications
of multiple clusters of gene lists with a reference list (list of all
genes in our array) and to statistically determine over- or
underrepresentation of PANTHER classification categories.
Each list was compared with the reference list, using the bino-
mial test for each molecular function, biological process, or
pathway term in PANTHER. A P value was determined using
the binomial statistic (that is, the probability that the number of
genes observed in each category occurred by chance [ran-
domly], as determined by the reference list). We selected a
cutoff of 0.05 to ensure the significance of biological proc-
esses and pathways within each ontology term. Compilation of
our clinical and experimental data complied with the recom-
mendations for Minimum Information About a Microarray
Experiment (MIAME), and the raw data have been deposited
[GEO: GSE13026] in the Gene Expression Omnibus (GEO)
repository [16].
Results
Transcriptome analysis of early versus long-standing 
rheumatoid arthritis
Using a t test with an adjusted Bonferroni P value of less than
0.01, we identified a combination of 719 genes differentially
regulated between early and LS RA samples (Figure 1a)Available online http://arthritis-research.com/content/11/3/R99
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(Table S2 in Additional data file 2). These genes clearly sepa-
rated early and LS RA. Among these 719 genes, 2 clusters (1
and 2) were distinct by their opposite gene-expression regula-
tions for each stage. In cluster 1, 503 genes were more
strongly expressed in early than LS RA. Based on gene ontol-
ogy, we subsequently identified 12 significant (P < 0.05) bio-
logical processes, including immunity and host defenses,
stress responses, T cell-mediated immunity, and tumor sup-
pressor and major histocompatibility complex (MHC) class II-
mediated immunity, whose corresponding genes were signifi-
cantly upregulated during early RA (Table S3 in Additional
data file 3). Many pathways involved in this gene cluster were
also significantly recognized (P  < 0.05): T-cell activation,
endothelin signaling pathway, hypoxia response, and plas-
minogen-activating cascade. In cluster 2, 216 genes were
expressed significantly more in LS than early RA. The main bio-
logical processes implicated in this cluster were cell cycle, cell
surface receptor-mediated signal transduction, cell cycle con-
trol, ligand-mediated signaling, apoptosis inhibition, and gran-
ulocyte-mediated immunity (Table S3 in Additional data file 3).
Overall, these findings showed that early and LS RA are distin-
guishable by their own molecular patterns. We observed that
some genes upregulated during early RA were more specifi-
cally involved in stress responses, defense mechanisms, and
apoptotic processes, whereas upregulated genes in LS RA
participated in proliferative processes.
Transcriptome analysis of early rheumatoid arthritis 
versus control synovia
To identify molecular mechanisms particularly involved in early
RA, we compared the gene-expression levels between early
RA and healthy synovia. These samples, too, clearly separated
into two clusters in early RA samples: cluster 1 contained 116
genes, 50 of which were downregulated, and cluster 2, con-
sisted of 66 upregulated genes (Figure 1b) (Table S4 in Addi-
tional data file 4). Cluster 1 significantly (P < 0.05) defined 6
biological processes, 5 predominant molecular functions, and
1 pathway, whereas the 66 genes in cluster 2 clearly involved
6 biological processes, 7 main molecular functions, and 2
pathways (Table 1).
Transcriptome analysis of long-standing rheumatoid 
arthritis versus control synovia
To identify the different biological processes represented in
LS RA as opposed to early RA, we compared LS RA and
healthy synovia. As shown in Figure 1c, 52 transcripts were
able to clearly discriminate between them (Table S5 in Addi-
tional data file 5). Among them, 36 (cluster 1) and 16 (cluster
2) genes, respectively, were significantly down- and upregu-
lated in LS RA compared with healthy synovia. Seven and
three biological processes and six and five different molecular
functions were identified in clusters 1 and 2, respectively,
along with three different pathways in each cluster (Table 2).
Overall, most of the ontological classes differed between early
and LS RA and therefore could be considered specific to the
disease stage. However, a few overlaps with opposite regula-
tions were observed. Indeed, regardless of the RA stage,
genes coding for metalloprotease inhibitors were downregu-
lated and those coding for the salvage pyrimidine deoxyribonu-
cleotide pathway were upregulated. These ontological classes
seemed to be disease-specific. Conversely, the genes of some
biological processes (protein biosynthesis and nucleoside,
nucleotide, and nucleic acid metabolism) and molecular func-
Figure 1
Hierarchical gene clustering in rheumatoid arthritis (RA) and control  synovia at different stages of progression Hierarchical gene clustering in rheumatoid arthritis (RA) and control 
synovia at different stages of progression. Samples from four early RA 
(eRA) patients, four long-standing RA (LS RA) patients, and seven con-
trols (C) were studied by microarray analysis. Transcripts were selected 
with a supervised statistical one-class t test with the adjusted Bonfer-
roni correction (P < 0.01). Patients are indicated as vertical column 
headings, and gene symbols of transcripts are given in horizontal rows. 
Transcript levels are expressed as the ratio sample level/median control 
level. Scale bar (log2 ratio): low (green), high (red), or ratio of 1 (black) 
expression in the sample versus the median control value (gray squares 
are missing values). (a) Visualization of 719 transcripts able to distin-
guish LS RA from early RA patients. (b) Visualization of 116 transcripts 
able to distinguish early RA patients from controls. (c) Visualization of 
52 transcripts able to distinguish LS RA patients from controls. Each 
clustering is divided in two, yielding clusters 1 and 2, indicated by verti-
cal bars.Arthritis Research & Therapy    Vol 11 No 3    Lequerré et al.
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Table 1
Ontological classes of differentially expressed genes in early rheumatoid arthritis versus controls
Gene regulation Early rheumatoid arthritis versus controls P value
Biological processes
Up (cluster 2)
Reverse transcription 0.007
Amino acid activation 0.01
Protein biosynthesisa 0.02
Nucleoside, nucleotide, and nucleic acid metabolisma 0.02
Protein metabolism and modification 0.03
Other immune and defense 0.04
Down (cluster 1)
Granulocyte-mediated immunity 0.0004
Other cell cycle process 0.01
Macrophage-mediated immunity 0.02
T cell-mediated immunity 0.03
Other blood circulation and gas exchange activity 0.04
Mitochondrial transport 0.05
Molecular functions
Up (cluster 2)
Ribosomal proteina 0.005
Reverse transcriptase 0.007
Nucleic acid binding 0.009
Other transcription factor 0.03
Defense/immunity protein 0.03
Nuclease 0.04
Antibacterial response protein 0.05
Down (cluster 1)
Transmembrane receptor regulatory/adaptor protein 0.008
Metalloprotease inhibitora 0.02
Phosphorylase 0.03
Protease inhibitor 0.03
Cysteine protease inhibitor 0.04
Pathways
Up (cluster 2)
Bupropion degradation 0.007
Salvage pyrimidine deoxyribonucleotidesa 0.01
Down (cluster 1)
Metabotropic glutamide receptor group I pathway 0.07
The gene-ontology terms used are those of the PANTHER (Protein ANalysis THrough Evolutionary Relationships) database. aCommon ontological 
classes found in both comparisons: early rheumatoid arthritis (RA) or long-standing RA versus controls (see also Table 2).Available online http://arthritis-research.com/content/11/3/R99
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Table 2
Ontological classes of differentially expressed genes in long-standing rheumatoid arthritis versus controls
Gene regulation Long-standing rheumatoid arthritis versus controls P value
Biological processes
Up (cluster 2)
Pheromone response 0.002
Chemosensory perception 0.002
Pyrimidine metabolism 0.03
Down (cluster 1)
Fatty acid beta oxidation 0.003
Protein biosynthesisa 0.007
Nucleoside, nucleotide, and nucleic acid metabolisma 0.009
Constitutive exocytosis 0.02
Vitamin biosynthesis 0.03
Amino acid transport 0.04
Fatty acid metabolism 0.04
Molecular functions
Up (cluster 2)
Serine protease 0.003
Interleukin receptor 0.02
Protease 0.03
Nucleotide kinase 0.04
Cytokine receptor 0.04
Down (cluster 1)
Storage protein 0.002
Ribosomal proteina 0.01
Metalloprotease inhibitora 0.02
Amino acid transporter 0.02
Extracellular matrix linker protein 0.02
Other receptor 0.04
Pathways
Up (cluster 2)
Salvage pyrimidine deoxyribonucleotidesa 0.003
Vasopressin synthesis 0.005
p38 MAPK pathway 0.03
Down (cluster 1)
Vitamin D metabolism and pathway 0.02
Histamine receptor-mediated signaling pathway 0.04
Enkephalin release 0.04
The gene-ontology terms used are those of the PANTHER (Protein ANalysis THrough Evolutionary Relationships) database. aCommon ontological 
classes found in both comparisons: early rheumatoid arthritis (RA) or long-standing RA versus controls (see also Table 1). MAPK, mitogen-
activated protein kinase.Arthritis Research & Therapy    Vol 11 No 3    Lequerré et al.
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tion (ribosomal protein) were differentially regulated and
stage-specific (Tables 1 and 2).
Discussion
A previous report [2] already showed that RA is a heterogene-
ous disease with distinct molecular forms, but to date, few
studies have focused on different RA stages [17]. Herein, we
showed, for the first time, that gene-expression profiling in syn-
ovia from patients with early untreated RA and those with
treated LS RA revealed opposite gene regulations, suggesting
the involvement of different pathophysiological mechanisms
during the disease course. Moreover, the novel comparison of
the gene-expression levels in early or LS RA with those
observed in healthy (mechanical or traumatic lesions) synovia
brings information that is more appropriate than that obtained
with osteoarthritis synovia (used as the reference in most of
the published studies). The synovial biopsies, taken from sites
of active RA-associated synovitis, enabled us to examine RA
molecular processes. In LS RA, because the biopsied joints
still harbored active disease, it seems likely that the pathophys-
iology and molecular processes were not influenced by meth-
otrexate or that, at worst, they were weakly influenced by
methotrexate.
The small number of samples and the fact that we did not per-
form a pangenomic study limit the possibility of making any dis-
tinction between RA with and RA without anti-cyclic
citrullinated peptide autoantibodies and thus of drawing puta-
tive pathophysiological conclusions. Indeed, the 12,000
cDNA probes covering our array were selected on the basis of
tissue-preferred expression in liver and corresponded to
genes with liver-restricted expression (10% of the probes) and
genes with combined hepatic and broad expression (the other
90%). Moreover, preliminary comparison with a pangenomic
array indicated that our array is able to detect more than two
thirds of the genes from healthy synovia (data not shown).
Because this restrictive procedure cannot measure every tran-
script expressed in the tissue, it is not intended to provide a
genome-wide view of the RA-associated gene dysregulations.
Nevertheless, our approach seems quite acceptable, as our
major task here was a preliminary study of molecular profiles in
early and LS RA versus control synovia.
These limitations aside, our observations identified several dif-
ferences in ontological processes, thereby also suggesting
several putative differences in the RA pathophysiological
mechanisms as a function of disease progression. In addition,
the distinct biological processes identified here according to
RA stage are compatible with our knowledge of its pathophys-
iology. Indeed, the genes linked to the biological processes,
referred to as MHC class II-mediated immunity, immunity and
defense, and T cell-mediated immunity, which represent the
hallmarks of immune system activation, were upregulated in
early RA. The antibacterial response, T cell-mediated immu-
nity, and macrophage-mediated immunity are also the main
functional and biological processes involved at RA onset.
Conversely, genes involved in the cell cycle, apoptosis inhibi-
tion, and granulocyte-mediated immunity were upregulated in
LS RA, suggesting the involvement of a proliferative process.
By identifying dysregulated genes in early and LS RA as com-
pared with healthy synovia, we provide arguments that the bio-
logical processes, molecular functions, and pathways differed
according to the stage.
However, the results of the comparisons, early or LS RA ver-
sus controls, seem to be contradictory for some biological
processes (Tables 1 and 2) (Table S3 in Additional data file 3).
For example, the genes involved in T cell-mediated immunity
were upregulated in early versus LS RA (HLAB, HLADRB1,
CLEC4M, and so on) but were downregulated in early versus
controls (IFFG1, LTB, and so on). These findings are not dis-
cordant, because the genes belonging to each class were dif-
ferent and did not overlap. Moreover, some processes/
pathways are common to early and LS RA but the expressions
of the genes belonging to these classes are subjected to
opposite regulations. For instance, genes for protein biosyn-
thesis, for nucleoside, nucleotide, and nucleic acid metabo-
lism, and for ribosomal proteins were upregulated in early RA
versus controls but were downregulated in LS RA versus con-
trols. These opposite regulations could reflect disease proc-
esses involved during the different stages of disease. On the
contrary, genes encoding metalloprotease inhibitor and sal-
vage pyrimidine deoxyribonucleotide ontological classes were
regulated similarly in early and LS RA. This overlap could
reflect an RA-specific mechanism, regardless of the disease
stage. But when we compared the gene sets involved in that
mechanism and those dysregulated in RA versus previously
published controls [2,17,18], we found only three genes in
common:CEBPβ, HCLS1, and TIMP1.
Notably, the age differences among controls and early RA and
LS RA patients might influence the results. Indeed, de Magal-
hães and colleagues [19] reported that gene expression rela-
tive to inflammation, immune response, lysosome, energy
metabolism, cell cycle, and cellular senescence could be
affected by the aging process. Consequently, it is conceivable
that differences observed herein could be explained, at least in
part, by age rather than RA. This limitation is very difficult to
avoid in clinical practice because restricting selection of RA
patients to those of the same age but with different RA stages
represents a real, if not impossible, challenge.
Previously, Olsen and colleagues [20] performed a similar
study on early and LS RA but they used peripheral blood
mononuclear cells (PBMCs) from patients being treated with
DMARDs or corticosteroids. The authors found that early RA
was associated with a distinct gene-expression profile in
PBMCs, with a signature that reflected an immune response
to an unidentified infectious agent. Despite the differences in
study designs, some families of genes (cytochrome P450,Available online http://arthritis-research.com/content/11/3/R99
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zinc-finger protein, chemokine receptors, MHC class II, and
RAS oncogene family) were common to their study and ours.
For example, the S100A10 gene was downregulated in both
early RA PBMCs and synovial tissues, whereas HLA-DPA1,
B2M, and ARHGDIB were dysregulated in early RA PBMCs
and synovial tissues. These latter discrepancies might be
explained by the differences between the tissues (PBMCs ver-
sus synovia) and the controls (vaccinated versus healthy
donors) used in the two studies. Even though these two stud-
ies are not completely comparable, some of their findings con-
verge, pointing to the involvement of stress responses and
defense mechanisms in early RA, and are therefore comple-
mentary, contributing to a better understanding of the different
RA stages.
Conclusions
The results of our microarray analysis show that the RA molec-
ular signature changes during disease progression. A better
understanding of the pathophysiological mechanisms involved
could contribute to the identification of targets that are more
specific and, hence, therapeutic tools that are more appropri-
ate. This approach might represent a novel way to improve and
optimize RA therapeutic strategies.
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